According to George Hollenberg, a leading NY-area pathologist and founder of Acupath Laboratories, researchers charged with updating the guidelines for the diagnosis and treatment of Melanoma for the National Comprehensive Cancer Network are recommending a far more aggressive approach to catching the deadly skin cancer in its earliest, most treatable stage. The new guidelines from the NCCN - an alliance of 20 of the world's leading cancer research and treatment centers - encourage immediate full excisional biopsies of any suspicious new skin growths. (PRWEB May 19, 2006)

According to Dr. George Hollenberg, a leading pathology expert and founder of Acupath Laboratories in New York, "Each year, more than a million new cases of cancer are reported. The seriousness of these cases ranges from low risk to life threatening. The process of determining which is which is called staging."Staging provides a universal way for doctors to define the extent and severity of a cancer. Through staging, medical professionals can determine the best course of treatment for a patient." (PRWeb Nov 13, 2007)

According to Dr. George Hollenberg, a leading pathology expert and founder of Acupath Laboratories in New York, "Each year, more than a million new cases of cancer are reported. The seriousness of these cases ranges from low risk to life threatening. The process of determining which is which is called staging."Staging provides a universal way for doctors to define the extent and severity of a cancer. Through staging, medical professionals can determine the best course of treatment for a patient." (PRWeb Nov 13, 2007)

NEW YORK (Reuters Health) - Organ transplant recipients have a much higher than average risk of developing an aggressive form of skin cancer, called squamous cell carcinoma. Dermatologists want physicians, nurses and patients to be aware of this risk so that any skin growths that look suspicious can be treated as early as possible.

According to George Hollenberg, a leading NY-area pathologist and founder of Acupath Laboratories, Over the past decade, advances in cytogenetics testing have propelled researchers to an entirely new level of understanding where many cancers are concerned. Yet, even such an intricate testing process as conventional cytogenetics can have its limits, and scientists have found those limits in cytogenetics testing for two cancers in particular: Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM). The good news is that another testing process called I-FISH (Interphase Fluorescence In-Situ Hybridization, aka Molecular Cytogenetics) can augment conventional cytogenetics testing in cases of CLL and MM, providing doctors and patients with significant missing data that can lead to more accurate diagnosis, prognosis and treatment decisions.

According to George Hollenberg, a leading NY-area pathologist and founder of Acupath Laboratories, Over the past decade, advances in cytogenetics testing have propelled researchers to an entirely new level of understanding where many cancers are concerned. Yet, even such an intricate testing process as conventional cytogenetics can have its limits, and scientists have found those limits in cytogenetics testing for two cancers in particular: Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM). The good news is that another testing process called I-FISH (Interphase Fluorescence In-Situ Hybridization, aka Molecular Cytogenetics) can augment conventional cytogenetics testing in cases of CLL and MM, providing doctors and patients with significant missing data that can lead to more accurate diagnosis, prognosis and treatment decisions.

For the first time in 25 years, the breast cancer diagnosis rate among women in the U.S. has stabilized, and the number of deaths per year has declined each year since 1990. Yet, breast cancer is still the most commonly diagnosed non-skin cancer for American women. Pathology expert Dr. George Hollenberg offers a step-by-step screening process for most common women's cancer. (PRWeb Dec 1, 2006)

For the first time in 25 years, the breast cancer diagnosis rate among women in the U.S. has stabilized, and the number of deaths per year has declined each year since 1990. Yet, breast cancer is still the most commonly diagnosed non-skin cancer for American women. Pathology expert Dr. George Hollenberg offers a step-by-step screening process for most common women's cancer. (PRWeb Dec 1, 2006)